The world’s largest pesticide patent is about to expire, and many domestic companies are making plans.

After a huge loss of tens of billions, ST Hainan Airlines launched a tens of billions of fixed increase plan

On the evening of August 11, HNA Holdings (ST HNA) released a fixed increase plan, planning to pay Hanwei The investment in fixed-increase capital raising will not exceed 10.87 billion yuan, and all of it will be used to supplement working capital after deducting issuance expenses. The number of A shares in this non-public issuance is 9.972 billion shares, which does not exceed 30% of the company's total share capital before the issuance. The fixed increase price is 1.09 yuan/share, which is a discount of nearly 24% compared to yesterday's closing price.

ST HNA announced that Hanwei Investment, the object of this issuance, is a wholly-owned subsidiary established by HNA Aviation Group, a subsidiary of the company’s controlling shareholder Fangda Aviation. The announcement reminded that after this private placement, the company’s controlling shareholder will be changed from Fangda Aviation to Hanwei Investment, and the actual controller will still be Fang Wei.

For the purpose of private placement, the company stated that, first, the controlling shareholder will provide financial support to boost market confidence and provide guarantee for the company's business development; second, it will improve the capital structure and enhance the company's ability to resist risks and financial stability. .

It is worth noting that this is the first time HNA has disclosed its financing plan after the thunderstorm. The company’s last private placement was traced back to September 2016. At that time, it raised 16.4 billion yuan in private placement, which was the first time the company went public. The fourth fixed increase since then.

ST Hainan Airlines has disclosed its semi-annual report preview. The loss range in the first half of the year is 11.95 billion yuan to 12.96 billion yuan. In other words, the 10.8 billion yuan raised this time cannot make up for the losses in the first half of the year.

Based on the upper limit of forecasted net profit, ST Hainan Airlines’ losses in the first half of the year ranked third after Air China and China Eastern Airlines. In addition, China Southern Airlines’ losses in the first half of the year also exceeded 10 billion. Affected by the epidemic in the first half of the year, the entire civil aviation industry was in a difficult period. Judging from the seven A-share civil aviation stocks that have issued notices, the total losses in the first half of the year ranged from 61.3 billion yuan to 69.8 billion yuan.

Just the day before, ST HNA also announced that it had received the "Advance Notice of Administrative Penalty" from the China Securities Regulatory Commission, imposing a total fine of 3 million yuan. The main reason for the penalty was letter disclosure violations: as a subsidiary of HNA Group The company lacks independence in financial capital management and control, and the company’s related related transactions and guarantees have not been disclosed.

At the same time, as many as 11 senior executives who signed ST HNA Holdings’ annual report and semi-annual report were punished accordingly. That night, a group of four ST HNA executives, including the director, vice president and secretary to the board, announced their resignation.

Affected by the negative news, ST HNA closed at the daily limit yesterday, with the latest price quoted at 1.38 yuan. However, ST HNA's share price has still fallen by more than 25% this year, which is half of last year's rebound high point.

The patent for the world’s best-selling insecticide product is about to expire

According to reports, FMC’s star insecticide product chlorantraniliprole (drug name: Kangkuan) The patent expires in August this year. According to inquiries from the State Intellectual Property Office, the patent application date was August 13, 2002. According to the invention patent term, it is 20 years, and the expiration date is August 13, 2022.

Chlorantraniliprole (Kangkuan) is currently the most popular pesticide on the market and can be called the highest-selling pesticide in every country. It is a high-efficiency broad-spectrum insecticide that can control most chewing mouthpart pests, especially Lepidoptera pests. It has good control effects on Lepidoptera, Noctuidae, Botryidae, Fruit-boring Moths, etc. . In 2019, the global sales of chlorantraniliprole were US$1.581 billion, ranking first in the insecticide category.

Global sales of chlorantraniliprole in 2020 were US$1.725 billion. Sales of patented Fumeishi chlorantraniliprole were US$1.5 billion, with a market share of 87. According to 360 Research Reports, the market size of chlorantraniliprole in 2027 will be US$2.332 billion, with a compound growth rate of 4.4 from 2021 to 2027.

Leading stocks surged over 40% in 7 days

Affected by the expiration of patents, A-share chlorantraniliprole concept stocks have been relatively active recently. Hailier has been There were 7 consecutive positive days, including two consecutive days of daily limit increases on August 5th and 7th, with a cumulative increase of more than 40%. According to public information, the Hailier Hengning project will be constructed in two phases. After the second phase of construction, the production capacity will be 1,000 tons of chlorantraniliprole.

The stock price of Shanshui Technology rose to the 20CM limit on August 8. The company’s 2,3-dichloropyridine is the core of DuPont’s star patented insecticide product chlorantraniliprole (also known as Kangkuan) Raw materials, the existing production capacity is 550 tons, and 8,000 tons are under construction.

The trend of Red Sun is ever-growing, with an increase of 84% since the beginning of this year. The company expects to build a chlorantraniliprole industrial chain production capacity of 35,000 tons/year in 2025.

Currently, many domestic companies have laid out the industrial chain of chlorantraniliprole technical material and intermediates. After reaching full production, they can form a production capacity of 57,000 tons of technical material and 15,050 tons of intermediates. Taking advantage of cost advantages and scale dividends, Seize the market after the patent expires in August 2022. In addition to the above three companies, there are many listed companies that have deployed chlorantraniliprole. For details, see:

The project construction of Changqing (Hubei) Biotechnology Co., Ltd., a wholly-owned subsidiary of Changqing Co., Ltd., has been completed and put into production. It will later be able to produce 1,000 tons of chlorantraniliprole technical material annually.

The project of the wholly-owned subsidiary of Guangxin Co., Ltd. will be implemented in two phases. After the construction of the second phase, the production capacity will be 1,000 tons of chlorantraniliprole. Nopson has obtained registration for chlorantraniliprole products.

Leer Chemical said it has developed a series of new products such as chlorantraniliprole. (Data Baolin Lifeng) Statement: All information content of Data Bao does not constitute investment advice. The stock market is risky, so investment needs to be cautious.

If you want to know more real-time financial news, please follow us.